Article
Oncology
Shun Tasaka, Keiichi Jingu, Noriyoshi Takahashi, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Kazuya Takeda, Yu Suzuki, Noriyuki Kadoya
Summary: This study evaluated the long-term change of parotid gland volume after IMRT in nasopharyngeal carcinoma patients, finding a gradual recovery in volume even three years post-radiotherapy, especially in parotids receiving less than 40 Gy as the mean dose. Additionally, the mean irradiated dose for bilateral parotids was negatively correlated with oral QOL score and oral moisture after a long period.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Fen Xue, Xiaoshuang Niu, Chaosu Hu, Xiayun He
Summary: This study aimed to determine the long-term risk of second primary lung adenocarcinoma (SPLAC) in nasopharyngeal cancer (NPC) patients after intensity-modulated radiotherapy (IMRT). The results showed that the incidence of SPLAC in NPC patients after IMRT was similar to that of the normal population, and most cases were detected in early stages during follow-up, with good surgical efficacy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Guanzhu Shen, Yinglin Peng, Jian Li, Haijun Wu, Guangshun Zhang, Chong Zhao, Xiaowu Deng
Summary: This study evaluated the incidence of hypothyroidism in patients with nasopharyngeal carcinoma after IMRT, finding that 34.8% of patients developed hypothyroidism 12 months after radiotherapy. The average thyroid dose and thyroid volume were identified as key factors affecting hypothyroidism, with an NTCP model constructed based on these factors showing good fit.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yi-Jun Hua, Yan-Feng Ou-Yang, Xiong Zou, Le Xia, Dong-Hua Luo, Ming-Yuan Chen
Summary: Radiotherapy is crucial for nasopharyngeal carcinoma patients, with a typical treatment duration of six to six and a half weeks. Prolonged radiotherapy duration is associated with higher risk of distant metastasis and death, highlighting the importance of avoiding prolonged treatment to improve outcomes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Kaixuan Yang, Wenji Xie, Xiangbin Zhang, Yu Wang, Arthur Shou, Qiang Wang, Jiangfang Tian, Jiangping Yang, Guangjun Li
Summary: This study aimed to predict late radiation xerostomia and successfully developed a predictive model, which can effectively improve patients' quality of life.
Article
Oncology
Ruiping Zhai, Yingchen Lyu, Mengshan Ni, Fangfang Kong, Chengrun Du, Chaosu Hu, Hongmei Ying
Summary: The study aims to identify factors predicting the risk of hypothyroidism in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy (IMRT). The findings suggest that younger age, female gender, and small thyroid volume are the most important factors predicting hypothyroidism risk. Thyroid volume Vt40 is a key parameter in predicting the risk of hypothyroidism after IMRT in nasopharyngeal carcinoma patients.
RADIATION ONCOLOGY
(2022)
Article
Oncology
Xin-Bin Pan, Yang Liu, Shi-Ting Huang, Su Pei, Kai-Hua Chen, Song Qu, Ling Li, Xiao-Dong Zhu
Summary: The study found that V30 of the parotid glands is a major predictive factor for grades 2-3 xerostomia in nasopharyngeal carcinoma patients, while the dose and volume of the submandibular glands are not independent predictive factors.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Qiaojuan Guo, Nan Xiao, Hanchuan Xu, Jingfeng Zong, Youping Xiao, Tianzhu Lu, Yun Xu, Bingyi Wang, Bijuan Chen, Jianji Pan, Shaojun Lin
Summary: This study investigated the feasibility of level Ib sparing in selected nasopharyngeal carcinoma patients during intensity-modulated radiation therapy based on the International Guideline. The results showed that level Ib-sparing IMRT is safe and feasible for patients who meet certain criteria.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Oncology
Jianzhong Cao, Xiaodong Zhang, Bo Jiang, Jiayun Chen, Xiaochun Wang, Li Wang, Narayan Sahoo, X. Ronald Zhu, Rong Ye, Pierre Blanchard, Adam S. Garden, C. David Fuller, G. Brandon Gunn, Steven J. Frank
Summary: The study showed that in patients with oropharyngeal cancer, IMPT treatment was associated with less late xerostomia compared to IMRT treatment. Dosimetric variables related to the oral cavity were associated with late xerostomia.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Lin Chen, Jing Li, Kunpeng Li, Jiang Hu, Qingjie Li, Chenglong Huang, Gaoyuan Wang, Na Liu, Linglong Tang
Summary: This study analyzed the probability of hearing impairment after radiotherapy for nasopharyngeal carcinoma and developed a predictive model, providing dose limitation suggestions to improve patients' quality of life.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Da-wei Zhao, Feng Teng, Ling-ling Meng, Wen-jun Fan, Yan-rong Luo, Hua-yong Jiang, Nan-xiang Chen, Xin-xin Zhang, Wei Yu, Bo-ning Cai, Lu-jun Zhao, Pei-guo Wang, Lin Ma
Summary: The purpose of this study is to create and validate a comprehensive predictive model for the transition from moderate-severe to normal-mild xerostomia after radiotherapy in patients with nasopharyngeal carcinoma (NPC). The prediction model includes age, gender, post-radiotherapy xerostomia questionnaire scores, and mean dose delivered to specific glands. The model showed good discrimination and calibration in both internal and external validation cohorts. Sparing the submandibular gland (SMG) is crucial for the patient's recovery.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Huageng Huang, Jingjing Miao, Xiao Xiao, Jiang Hu, Guangshun Zhang, Yinglin Peng, Shunzhen Lu, Yingshan Liang, Shaomin Huang, Fei Han, Xiaowu Deng, Chong Zhao, Lin Wang
Summary: This study compares the incidence of xerostomia in nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT) and conventional IMRT (C-IMRT). The results show that SPLS-IMRT significantly reduces the incidence of xerostomia compared to C-IMRT, while also promoting earlier recovery of parotid gland function without compromising survival outcomes.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Otorhinolaryngology
Jing-Jin Weng, Jia-Zhang Wei, Min Li, Le-Ping Ning, Fei Liu, Yun-Zhong Wei, Wei-Ming Xiong, Ben-Jian Zhang, Jin-Long Lu, He Jiang, Qiu-Tian Lu, Shen-Hong Qu
Summary: This study aimed to investigate the effect of hypothyroidism and thyroxine replacement therapy on the prognosis of nasopharyngeal carcinoma (NPC) patients. The results showed that patients with hypothyroidism had better survival rates. Hypothyroidism was identified as a positive independent prognostic factor. Thyroxine replacement therapy did not negatively affect the survival rates of these patients.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2022)
Article
Otorhinolaryngology
Xixi Liu, Bian Wu, Jing Huang, You Qin, Zhanjie Zhang, Liangliang Shi, Xiaohua Hong, Qian Ding, Gang Peng, Kunyu Yang
Summary: This study aims to identify tumor factors associated with in-field failure in patients with nasopharyngeal carcinoma (NPC) receiving intensity-modulated radiotherapy (IMRT). The results showed that in-field failure was the major pattern of recurrence in NPC patients. Large tumor volume, nonkeratinizing differentiated carcinoma, and cervical nodal necrosis were independent tumor factors associated with in-field failure.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2022)
Review
Otorhinolaryngology
Yongyuan Xue, Guoping Li, Tao Xie, Hongyang Xu, Tianrui Xu, Zhengfei Li, Lixiu Zhu, Xin Li, Zhiyao Li, Wei Xiong
Summary: This study systematically reviewed the significance of concurrent chemoradiotherapy for stage II nasopharyngeal cancer. The results showed that in the era of intensity-modulated radiotherapy, concurrent chemoradiotherapy and radiotherapy alone have the same survival benefits and concurrent chemoradiotherapy increases acute hematological toxicity. Subgroup analysis showed that for people with N1 nasopharyngeal cancer at risk of distant metastases, concurrent chemoradiotherapy and radiotherapy alone also had equal survival benefits.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
(2023)
Article
Oncology
Derek A. Mumaw, Allison J. Hazy, Aleksander Vayntraub, Thomas J. Quinn, Kamran Salari, John H. Chang, Noah Kalman, Sanford Katz, James Urbanic, Robert H. Press, Arpi Thukral, Henry Tsai, George E. Laramore, Jason Molitoris, Carlos Vargas, Samir H. Patel, Craig Stevens, Rohan L. Deraniyagala
Summary: This study evaluated contralateral recurrences in patients with oropharyngeal squamous cell carcinoma who received unilateral proton beam therapy. The results showed a favorable contralateral neck failure rate that was comparable to photon irradiation.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Kangpyo Kim, Dongryul Oh, Jae Myoung Noh, Yang Won Min, Hong Kwan Kim, Yong Chan Ahn
Summary: This study suggests that hypofractionated radiation therapy alone is a feasible option for early stage esophageal squamous cell carcinoma patients. Particularly, in patients with tumor length < 3 cm, this treatment scheme shows favorable local control rates with low incidence of esophageal toxicities.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Lin Chen, Jing Li, Kunpeng Li, Jiang Hu, Qingjie Li, Chenglong Huang, Gaoyuan Wang, Na Liu, Linglong Tang
Summary: This study analyzed the probability of hearing impairment after radiotherapy for nasopharyngeal carcinoma and developed a predictive model, providing dose limitation suggestions to improve patients' quality of life.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Yiwei Yang, Jianxin Wang, Feng Gao, Zhen Liu, Tangzhi Dai, Haowen Zhang, Hongyu Zhu, Tingting Wang, Dexin Xiao, Kui Zhou, Zheng Zhou, Dai Wu, Xiaobo Du, Sen Bai
Summary: This paper provides a comprehensive description of the current status of PARTER, which is the first experimental FLASH platform utilizing megavoltage X-rays. It showcases the reliable performance and stability of the dosimeters and monitors used in PARTER, as well as the satisfactory dose distribution and characteristics of the FLASH X-rays. The platform effectively meets the requirements of preclinical research on megavoltage X-ray FLASH and undergoes continuous upgrades.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Maria Thor, Kelly Fitzgerald, Aditya Apte, Jung Hun Oh, Aditi Iyer, Otasowie Odiase, Saad Nadeem, Ellen D. Yorke, Jamie Chaft, Abraham J. Wu, Michael Offin, Charles B. Simone Ii, Isabel Preeshagul, Daphna Y. Gelblum, Daniel Gomez, Joseph O. Deasy, Andreas Rimner
Summary: The purpose of this study was to identify predictors of disease progression in early-stage non-small cell lung cancer (NSCLC) patients after receiving definitive stereotactic body radiation therapy (SBRT). The results showed that tumor diameter and SUVmax were the most frequently reported features associated with progression/survival, and a re-fitted model including these two features had the best performance.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Yong-Qiao He, Tong-Min Wang, Da-Wei Yang, Wen-Qiong Xue, Chang-Mi Deng, Dan-Hua Li, Wen-Li Zhang, Ying Liao, Ruo-Wen Xiao, Lu-Ting Luo, Hua Diao, Xia-Ting Tong, Yan-Xia Wu, Xue-Yin Chen, Jiang-Bo Zhang, Ting Zhou, Xi-Zhao Li, Pei-Fen Zhang, Xiao-Hui Zheng, Shao-Dan Zhang, Ye-Zhu Hu, Guan-Qun Zhou, Jun Ma, Ying Sun, Wei-Hua Jia
Summary: In this study, researchers aimed to establish a predictive model for radiation-induced brain injury (RBI) in nasopharyngeal carcinoma (NPC) patients by incorporating clinical factors and newly developed genetic variants. They conducted a large-scale retrospective study and a genome-wide association study to develop a polygenic risk score (PRS) for RBI risk prediction. The results showed that the PRS, combined with clinical factors, improved the accuracy of RBI risk stratification and suggested personalized radiotherapy.
RADIOTHERAPY AND ONCOLOGY
(2024)
Review
Oncology
Xiaoyong Xiang, Zhe Ji, Jing Jin
Summary: A review of studies suggests that brachytherapy as a salvage therapy for recurrent glioblastoma shows acceptable safety and good post-treatment clinical efficacy for selected patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
M. Berbee, C. T. Muijs, F. E. M. Voncken, L. Wee, M. Sosef, B. van Etten, J. W. van Sandick, F. A. R. M. Warmerdam, J. J. de Haan, E. Oldehinkel, J. M. van Dieren, L. Boersma, J. A. Langendijk, A. van der Schaaf, J. B. Reitsma, E. Schuit
Summary: This study externally validated a model for predicting 2-year total mortality in lung cancer patients in esophageal cancer patients. The intercept and/or slope of the original model needed adjustment to achieve good performance in esophageal cancer patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Dominique Reijtenbagh, Jeremy Godart, Joan Penninkhof, Sandra Quint, Andras Zolnay, Jan-Willem Mens, Mischa Hoogeman
Summary: This study compared the performance of the current PotD strategy with non-adaptive and fully online-adaptive techniques in the treatment of cervical cancer patients. The findings show that the PotD protocol is effective in improving normal tissue sparing compared to no adaptation, while fully online-adaptive approaches can further reduce target volume but come with a more complex workflow.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Albrecht Weiss, Steffen Loeck, Ting Xu, Zhongxing Liao, Aswin L. Hoffmann, Esther G. C. Troost
Summary: Traditional models for predicting radiation pneumonitis may not be applicable to non-small cell lung cancer patients treated with passively-scattered proton therapy. The use of effective alpha/beta parameter can predict the occurrence of radiation pneumonitis in these patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Z. A. R. Gouw, J. Jeong, A. Rimner, N. Y. Lee, A. Jackson, A. Fu, J-j. Sonke, J. O. Deasy
Summary: This study investigates the effectiveness of non-uniform fractionation schedules in radiotherapy for early-stage non-small cell lung cancer. Through modeling, optimized schedules are proposed to minimize local failures and toxicity risk. The results suggest that non-standard primer shot fractionation can reduce hypoxia-induced radioresistance and improve treatment outcomes.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Sara Ronchi, Alessandro Cicchetti, Maria Bonora, Rossana Ingargiola, Anna Maria Camarda, Stefania Russo, Sara Imparato, Paolo Castelnuovo, Ernesto Pasquini, Piero Nicolai, Mohssen Ansarin, Michele Del Vecchio, Marco Benazzo, Ester Orlandi, Barbara Vischioni
Summary: This study evaluates the efficacy and toxicity of carbon ion radiotherapy (CIRT) in locally advanced head and neck mucosal melanoma patients. The results show that CIRT is safe and effective in treating the local region, and immunotherapy after relapse can improve overall survival. However, further prospective trials are needed to assess the role of targeted/immune- systemic therapy in this disease.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Dominik Wawrzuta, Justyna Klejdysz, Marzanna Chojnacka
Summary: This study analyzed articles about radiation oncology published in The New York Times since its inception in 1851, and identified changes in media sentiment and prevalent themes related to radiotherapy. The findings suggest an increasing negative sentiment in media coverage towards radiotherapy, with a shift towards reporting treatment errors, toxicity, and ineffectiveness.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Elaine Limkin, Pierre Blanchard, Benjamin Lacas, Jean Bourhis, Mahesh Parmar, Lisa Licitra, Quynh-Thu Le, Sue S. Yom, Catherine Fortpied, Johannes Langendijk, Jan B. Vermorken, Jacques Bernier, Jens Overgaard, Jonathan Harris, Jean-Pierre Pignon, Anne Auperin
Summary: This study investigated the impact of season of radiotherapy on the outcomes of head and neck squamous cell cancer patients. The results showed that the season of radiotherapy did not have any significant effect on patient outcomes.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Fabio L. Cury, Gustavo A. Viani, Andre G. Gouveia, Camila V. S. Freire, Gabriel de A. Grisi, Fabio Y. Moraes
Summary: In limb-sparing treatment of soft tissue sarcoma patients, a 5-day course of preoperative radiotherapy results in high local control and favorable R0 margins, with acceptable complication rates, particularly for patients receiving higher biological equivalent doses.
RADIOTHERAPY AND ONCOLOGY
(2024)